Search clinical trials for: trifunctional antibody

Total 5256 results

National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

Mucopolysaccharidosis I | Hurler's Syndrome | Hurler-Scheie Syndrome | Scheie's Syndrome

United States
TaiMed Biologics Inc.

Completed

Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 (TMB-202)

HIV

Puerto Rico, United States
Peking Union Medical College Hospital

Unknown

Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis

Microscopic Polyangiitis | Granulomatosis With Polyangiitis | ANCA-associated Vasculitis | EosinphilicGranulomatosis With Polyangiitis

China
National Cancer Institute (NCI)

Terminated

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

Recurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical Carcinoma

United States
Centocor, Inc.
Schering-Plough

Completed

An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy (GO-FORWARD)

Rheumatoid Arthritis

Australia, Poland, United States, Germany, Argentina, Canada, Korea, Republic of, Chile, New Zealand, Taiwan, Mexico, Hungary
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Unspecified Childhood Solid Tumor, Protocol Specific

United States, Canada
Seoul National University Hospital
Dong-A Pharmaceutical Co., Ltd.

Terminated

Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure (ULTIMATE-SHF)

Systolic Heart Failure

Korea, Republic of
Peregrine Pharmaceuticals

Completed

Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse

Glioblastoma Multiforme

United States, India
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Seagen Inc.

Withdrawn

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Hematopoietic/Lymphoid Cancer

United States
National Cancer Institute (NCI)

Completed

CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recurrent Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage III Colon Cancer | Stage III Rectal Cancer

United States
ThromboGenics
BioInvent International AB

Completed

A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers

Healthy

Denmark
Light Chain Bioscience - Novimmune SA

Terminated

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (PIANO)

Primary Biliary Cirrhosis

Italy, United Kingdom
Pfizer

Terminated

A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Advanced Non-Hematologic Malignancies

United States, United Kingdom
National Cancer Institute (NCI)

Completed

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

Clear Cell Renal Cell Carcinoma | Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell Cancer

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Absolute Bioavailability of Reslizumab in Healthy Subjects

Absolute Bioavailability

United States
Cancer Advances Inc.

Completed

An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma (PC1)

Pancreatic Cancer
Cancer Advances Inc.

Completed

Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.

Pancreatic Cancer | Jaundice
Theraclone Sciences, Inc.

Completed

Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

Cytomegalovirus Infections

United States
PT Bio Farma

Completed

Evaluation on Immunogenicity and Safety Profile of Trivalent OPV (tOPV Bio Farma)

Healthy

Indonesia
Genzyme, a Sanofi Company

Completed

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

Melanoma | Carcinoma, Renal Cell

United States
Nanfang Hospital of Southern Medical University

Unknown

a Single-center Registered Clinical Research of Chinese Patients With Moderate to Severe Crohn's Disease

Serological C Reactive Protein or Erythrocyte Sedimentation Rate
National Cancer Institute (NCI)

Terminated

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage II Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer

United States
Avaxia Biologics, Incorporated

Completed

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

Ulcerative Colitis

United States, Hungary, Belgium, Canada
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma
Crucell Holland BV

Completed

Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns

Hepatitis B

China
Crucell Holland BV
National Institutes of Health (NIH); Division of Microbiology and Infectious...

Withdrawn

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

Influenza

United States, Australia, Canada, France, Germany, Spain, Belgium, Bulgaria, Netherlands, Brazil, South Africa, Sweden
Imperial College London
CUT'HIVAC Cutaneous HIV Vaccination

Unknown

Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via Intramuscular, Intradermal and Transcutaneous Routes (CUT*HIVAC001)

HIV

United Kingdom
Innate Pharma

Completed

A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia

Acute Myeloid Leukemia

France
Merck KGaA, Darmstadt, Germany

Terminated

TRUST Study: Raptiva ® in Hand & Foot Psoriasis (TRUST)

Chronic Plaque Psoriasis

Austria
Matthias Schwab

Terminated

Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing (GERD)

Gastroesophageal Reflux

Germany
Philogen S.p.A.

Completed

131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors

Brain Metastases From Solid Tumors

Italy, United Kingdom
Philogen S.p.A.
Syneos Health

Completed

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Advanced Solid Tumours

Italy, Germany
Philogen S.p.A.

Terminated

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Breast Cancer | Advanced Solid Tumor

Italy
Philogen S.p.A.
Eudax S.r.l.

Terminated

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Metastatic Melanoma

Switzerland, Italy, Austria, Germany
Philogen S.p.A.
Eudax S.r.l.

Completed

A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

Cancer

Italy
National Cancer Institute (NCI)

Completed

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children

Dengue Fever

Thailand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States, Canada, Australia
National Cancer Institute (NCI)

Completed

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
Sanofi Pasteur, a Sanofi Company

Terminated

Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults

Meningitis | Meningococcemia

United Kingdom
Eisai Co., Ltd.

Completed

A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)

Healthy Male Volunteers

Japan
Merck KGaA, Darmstadt, Germany

Terminated

ChangE From Any Systemic psoriasiS therapY to Raptiva (EASY)

Chronic Plaque Psoriasis

Canada
UCB Pharma

Completed

Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Japan
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
Novartis

Completed

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Germany, Belgium, Spain, Austria, Canada
Novartis Pharmaceuticals

Completed

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study (β-RELIEVED)

Acute Gout

Colombia, Switzerland, Germany, Russian Federation, Singapore, Australia, Belgium, Canada, Estonia, Guatemala, Latvia, Lithuania, Mexico, Norway, Poland, Sweden, Ukraine
Novartis Pharmaceuticals

Completed

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. (β-RELIEVED-II)

Acute Gout

United States, Canada, Russian Federation, Netherlands, China

Search clinical trials for: trifunctional antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations